California Defective Medical Device Lawyer: Riegel PMA Preemption, 510(k) Litigation, and Current MDL Framework

HOME › CALIFORNIA PERSONAL INJURY › PRODUCT LIABILITY AND ABUSE › DEFECTIVE MEDICAL DEVICE

Last updated: April 2026 — Reflects California strict product liability doctrine under Greenman v. Yuba Power Products, Inc. (1963) 59 Cal.2d 57, the U.S. Supreme Court's medical device preemption framework under Riegel v. Medtronic, Inc. (2008) 552 U.S. 312, Medtronic, Inc. v. Lohr (1996) 518 U.S. 470, and Buckman Co. v. Plaintiffs' Legal Comm. 

California defective medical device litigation is dominated by the federal preemption doctrine. The device's FDA classification — Class I, Class II, or Class III — and the specific regulatory pathway through which it entered the market determine which categories of state-law claims can proceed against the manufacturer.

The Riegel v. Medtronic framework creates near-total preemption for Class III Pre-Market Approval (PMA) devices, while 510(k) cleared Class II devices remain subject to standard California strict product liability under Greenman.

The parallel claims exception preserves claims that do not impose requirements different from or in addition to federal requirements — a "narrow gap" in the preemption framework that defines much of modern California medical device litigation.

The practical implications are significant. Patients injured by Class III PMA devices face substantial preemption defenses that narrow the claim pathways available to them.

Patients injured by 510(k) devices face standard California product liability litigation without the Class III preemption overlay. Understanding which framework applies is the first analytical step in every California defective medical device case. For the broader product liability and abuse framework, see our California Product Liability and Abuse guide.

FDA Medical Device Classification Framework

The FDA classifies medical devices into three categories based on the level of risk the device poses to the patient and the level of regulatory oversight required to assure safety and effectiveness.

Class I devices — low-risk devices subject only to general controls. Examples include elastic bandages, examination gloves, surgical drapes, bedpans, and other basic medical equipment. Most Class I devices are exempt from premarket notification requirements. California state law claims against Class I devices face no preemption from FDA general controls alone.

Class II devices — moderate-risk devices subject to general controls plus special controls, typically requiring 510(k) premarket notification. The 510(k) pathway requires the manufacturer to demonstrate substantial equivalence to a legally marketed predicate device.

Class II examples include infusion pumps, surgical instruments, catheters, powered wheelchairs, and many medical imaging devices. The 510(k) pathway does not involve independent FDA determination of safety and effectiveness — substantial equivalence analysis is comparative rather than evaluative.

Class III devices — high-risk devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. Class III devices require Pre-Market Approval (PMA), a rigorous scientific and regulatory review involving extensive clinical data. Class III examples include implantable cardioverter-defibrillators, pacemakers, mechanical heart valves, deep brain stimulators, and cochlear implants.

The distinction between 510(k) and PMA devices is fundamental to the preemption analysis. PMA devices face device-specific federal requirements established through the FDA's PMA review; 510(k) devices face only general federal requirements of substantial equivalence without device-specific safety and effectiveness determinations.

Riegel Preemption for Class III PMA Devices

In Riegel v. Medtronic, Inc. (2008) 552 U.S. 312, the U.S. Supreme Court held that the Medical Device Amendments express preemption provision under 21 U.S.C. § 360k(a) preempts state law tort claims against Class III PMA devices when those claims would impose requirements "different from, or in addition to" the federal requirements established through the PMA process.

The Court reasoned that the PMA process produces device-specific federal requirements and that common law tort claims impose state requirements that could conflict with FDA-approved design, manufacturing, and labeling specifications.

The practical effect of Riegel has been substantial preemption of state law tort claims against Class III PMA devices. The Court affirmed dismissal of the plaintiff's claims for strict products liability, breach of implied warranty, and negligence — the core California product liability claim categories. Across federal and state courts, Riegel preemption has dismissed claims relating to Class III PMA device design, manufacturing processes, and warning labels.

Buckman Implied Preemption. Buckman Co. v. Plaintiffs' Legal Comm. (2001) 531 U.S. 341 established implied preemption for state law claims premised on fraud-on-FDA theories. The Court held that federal enforcement of the FDCA is committed to the FDA, and that state law claims seeking to enforce FDCA compliance are impliedly preempted because they interfere with the FDA's exclusive enforcement authority. The Buckman implied preemption rule operates alongside Riegel's express preemption to create a dual preemption shield for PMA devices.

The Narrow Gap. Courts have described a "narrow gap" between Riegel's express preemption and Buckman's implied preemption. To survive both, a plaintiff must allege conduct that violates state tort law AND that violates a federal requirement — but cannot rely on the FDCA violation itself as the substantive basis for the claim. The plaintiff must be suing for conduct that violates the FDCA but not because it violates the FDCA.

Parallel Claims Exception

Riegel preserved a narrow exception for state law claims that "parallel" federal requirements — claims that seek to impose requirements identical to federal requirements rather than different or additional requirements. The parallel claims exception is the primary pathway for California plaintiffs pursuing Class III PMA device cases.

Elements of a valid parallel claim:

• State tort law duty (typically California strict product liability or negligence under Greenman and its progeny)

• The same conduct that violates the state duty also violates a federal requirement imposed through the PMA process or post-approval FDA regulation

• The state law claim does not impose any requirement different from or in addition to the federal requirement

• The plaintiff alleges specific federal violations with factual particularity sufficient to satisfy Bell Atlantic Corp. v. Twombly (2007) pleading standards

Common parallel claim categories:

• Manufacturing defect claims where the device departed from FDA-approved manufacturing specifications — typically the strongest parallel claim category because manufacturing defect cases focus on FDA compliance rather than FDA-approved specifications

• Failure-to-report adverse events based on the manufacturer's federal post-approval reporting obligations (Stengel v. Medtronic, Inc. (9th Cir. 2013) 704 F.3d 1224 permitted such claims under California state law, though subsequent circuit splits have narrowed the theory)

• Failure-to-follow FDA-mandated manufacturing practices under 21 CFR Part 820 and the Quality Management System Regulation

• Misbranding claims where the manufacturer's actual labeling departed from FDA-approved labeling

The parallel claims exception is narrow but meaningful. Experienced counsel identifies specific violations of federal requirements and frames California state-law claims to parallel those requirements precisely, thereby preserving the claim from preemption dismissal.

Class II Device Litigation — No Preemption

510(k) cleared Class II devices are not preempted under Riegel.

The Supreme Court in Medtronic, Inc. v. Lohr (1996) 518 U.S. 470 held that 510(k) clearance does not involve FDA determination of safety and effectiveness — substantial equivalence analysis is comparative, not evaluative — and therefore does not produce device-specific federal requirements that could preempt state law.

California Product Liability Framework for Class II Devices

Legal Framework	Class III (PMA)	Class II (510(k))
Preemption status	Substantial preemption under Riegel	No preemption under Lohr
Manufacturing defect claims	Parallel claims only	Full California strict liability
Design defect claims	Preempted	Full California strict liability under Barker
Failure-to-warn claims	Parallel claims only (narrow)	Full California failure-to-warn
Breach of warranty	Preempted (most claims)	Available under California UCC
Negligence	Parallel claims only	Available

For Class II devices, California plaintiffs pursue the full range of strict product liability and negligence theories without the Riegel preemption overlay. The Greenman strict liability framework applies fully, with the three defect categories (manufacturing, design, warning) all available.

Design defect analysis for Class II devices. California applies the dual Barker v. Lull Engineering Co. (1978) 20 Cal.3d 413 test: the consumer expectation test and the risk-benefit test. Class II device design defect cases frequently involve the risk-benefit test, with expert testimony addressing whether feasible alternative designs would have reduced injury risk without rendering the device unsuitable for its intended use.

Failure-to-warn analysis for Class II devices. California's learned intermediary doctrine under Carlin v. Superior Court (1996) 13 Cal.4th 1104 applies. The manufacturer's warning obligation extends to the prescribing physician or medical device practitioner, not directly to the patient. Failure-to-warn cases focus on the adequacy of device documentation provided to healthcare providers.

Specific Device Categories in Current Litigation

The current California defective medical device landscape includes several active high-volume categories across both PMA and 510(k) classifications.

IVC Filters. Inferior vena cava filters are temporary or permanent devices implanted in the inferior vena cava to prevent pulmonary embolism. Alleged complications include filter migration, filter fracture, organ perforation, and deep vein thrombosis. The Bard IVC filter MDL (MDL 2641) closed in 2023 with confidential settlements. The Cook IVC filter MDL (MDL 2570) in the Southern District of Indiana remains active. Most IVC filters are 510(k) cleared Class II devices, preserving full California product liability claim categories.

Bard PowerPort Catheters. Implantable vascular access devices alleged to fracture or break, causing catheter fragment migration, venous injury, and infection. MDL 3081 in the District of Arizona consolidates cases before Judge David G. Campbell (who also oversaw the Bard IVC filter MDL). The first bellwether trial is scheduled for April 2026. More than 2,800 cases are pending.

Paragard IUD. Non-hormonal copper intrauterine contraceptive device alleged to break apart during removal, leaving device fragments embedded in the uterus or migrating to other organs. Alleged injuries include uterine perforation, organ damage, infertility, infection, and need for invasive surgery. MDL 2974 consolidates approximately 3,900 cases with the first bellwether trial that began in January 2026. Paragard is a 510(k) cleared Class II device.

Philips CPAP and BiPAP Machines. Continuous positive airway pressure devices used for sleep apnea. A 2021 recall addressed polyester-based polyurethane (PE-PUR) foam degradation, with foam particles allegedly inhaled or swallowed by users. Alleged injuries include lung damage, cancer, and other respiratory and systemic complications. MDL 3014 in the Western District of Pennsylvania consolidates cases before Judge Joy Flowers Conti. CPAP devices are 510(k) cleared Class II devices.

Exactech Implants. Knee, hip, and ankle implants recalled for defective packaging that allowed oxygen infiltration causing accelerated polyethylene plastic component degradation. Alleged injuries include revision surgery, implant failure, bone loss, and ongoing pain. Product liability cases proceed in federal and state court. Most orthopedic implants are Class II or Class III depending on specific configuration.

Transvaginal Mesh. Surgical mesh for pelvic organ prolapse and stress urinary incontinence. Previously massive MDL litigation against multiple manufacturers has largely concluded through settlements exceeding $8 billion combined. Ongoing individual cases and potential future litigation against successor products continue in state and federal courts.

DePuy and Stryker Hip Implants. Metal-on-metal hip replacement devices alleged to cause metallosis (chromium and cobalt poisoning from implant wear) and revision surgery. DePuy ASR hip implants faced MDL 2197 with substantial settlements; Stryker hip implants similarly resolved through MDL proceedings. Ongoing revision and long-term complications continue to support individual cases.

Medtronic Infuse Bone Graft. Recombinant human bone morphogenetic protein device used in spinal fusion. Off-label use litigation has faced Riegel preemption challenges with mixed results. Medtronic Infuse is a Class III PMA device.

Essure Permanent Contraception Device. Permanent contraception device recalled and withdrawn from the U.S. market in 2018. Litigation resolved through Bayer/Conceptus settlements with over $1.6 billion in payouts; ongoing individual cases remain in state courts. Essure was a Class III PMA device, with substantial preemption challenges navigated through parallel claims theories.

MDL, JCCP, and Individual Litigation

California medical device plaintiffs face venue and procedural options parallel to the pharmaceutical litigation framework.

Federal Multidistrict Litigation (MDL). The Judicial Panel on Multidistrict Litigation consolidates related federal cases before a single judge. California plaintiffs in MDL cases benefit from consolidated discovery, aggregated settlement negotiations, and bellwether trial outcomes that often drive aggregate resolution. The MDL pathway is standard for high-volume device cases with common defendant and device issues.

California Judicial Council Coordination Proceeding (JCCP). The California state court equivalent, governed by CCP § 404 et seq. JCCP consolidates related California state court cases. Device cases with substantial California state court exposure routinely proceed through JCCP, and coordination between federal MDL and California JCCP proceedings is common in cases with both federal and California state court filings.

Individual state court litigation. Plaintiffs may pursue individual cases in California state court for strategic reasons — strong individual case facts, preference for California law application, favorable jury pools, or cases that do not qualify for MDL or JCCP consolidation.

Class action. Rare in modern medical device litigation due to individual causation and damages variability. Most current device cases proceed through MDL or JCCP rather than class action.

Damages in California Defective Medical Device Cases

Damages in California defective medical device cases include the standard product liability categories.

Economic damages include past and future medical expenses (often substantial in cases involving revision surgery, ongoing treatment, or permanent disability), lost earnings and earning capacity, home modification costs, attendant care costs, and related economic losses. Life care planning testimony is standard in cases involving permanent injury.

Non-economic damages include pain and suffering, emotional distress, disfigurement, and loss of enjoyment of life. Medical device non-economic damages are uncapped under California law — MICRA caps apply only to medical malpractice claims against healthcare providers, not to product liability claims against device manufacturers.

Punitive damages under Civil Code § 3294 are available when the manufacturer's conduct meets the malice, oppression, or fraud standard. Medical device punitive damages cases frequently involve documented evidence of manufacturer knowledge of defects that were concealed from regulators or physicians, failure to act on adverse event reports, or continued marketing despite documented safety concerns.

Wrongful death and survival damages in fatal cases. For the wrongful death framework applicable when a defective medical device causes death, see our California Product Liability Wrongful Death guide. Survival action damages under CCP § 377.30 are available for the decedent's economic damages; pre-death pain and suffering is no longer recoverable in ordinary survival actions filed on or after January 1, 2026 following the SB 447 sunset — see our California Survival Action guide.

Statute of Limitations

Ordinary product liability claims: Two years from the date of injury under CCP § 335.1.

Delayed discovery: Two years from discovery under the standard discovery rule, extending the deadline when the plaintiff could not reasonably have discovered the injury or its cause within the ordinary period. Delayed discovery is particularly relevant in implant cases where complications develop years after implantation.

Toxic exposure: Two years from discovery under CCP § 340.8 when the device injury involves exposure to toxic substances (including metallosis from metal-on-metal hip implants and foam degradation from CPAP devices).

Wrongful death: Two years from the date of death under CCP § 335.1.

Survival action: The longer of two years from death or six months after death if the personal injury limitations period had not expired at death, under CCP § 366.1.

Implant cases involving long-latency complications require careful statute of limitations analysis.

The discovery rule frequently extends filing deadlines when the causal connection between the device and the injury emerges only after manufacturer disclosures, FDA safety communications, or medical journal publications alert the patient to the connection.

Proving California Defective Medical Device Claims

The proof framework in California defective medical device cases involves several specialized evidentiary elements.

Device identification. Establishing the specific device, manufacturer, model number, lot number, and implant date. Medical records, surgical records, explant records, and registry records support identification. For revision cases, the explanted device itself is critical physical evidence requiring chain-of-custody preservation.

FDA regulatory classification and pathway. Determining whether the device is Class I, II, or III; whether it entered the market via 510(k), PMA, or other pathway; and what specific federal requirements apply. This analysis determines the preemption framework and available claim categories.

Defect theory development. Manufacturing defect cases require comparison of the specific device with FDA-approved specifications. Design defect cases (Class II only) require engineering expert testimony on alternative designs and risk-benefit analysis. Warning defect cases require analysis of device documentation provided to healthcare providers.

Medical causation. Expert testimony linking the device defect to the plaintiff's specific injury. Orthopedic surgeons, cardiologists, neurologists, and other medical specialists provide causation testimony depending on the device category. Epidemiological experts may testify about population-level risk evidence.

Manufacturer knowledge and misconduct. Internal company documents, adverse event reports, FDA correspondence (warning letters, 483 observations, recall records), and witness testimony establishing what the manufacturer knew about the defect, when they knew it, and how they responded. Particularly important for parallel claims (establishing federal violations) and punitive damages.

For PMA devices, parallel claim development. Specific identification of federal requirement violations — manufacturing process departures from PMA specifications, post-market surveillance failures, adverse event reporting failures, or Quality System Regulation violations — supporting state law claims that parallel federal requirements.

What to Do If You Were Injured by a Medical Device in California

Preserve the device if possible. For explanted devices, ensure proper chain of custody preservation. Hospitals and explanting surgeons should be instructed to preserve the device pending litigation evaluation. Device preservation is particularly important in manufacturing defect cases.

Obtain complete medical records. Records showing implantation, subsequent treatment, complication development, and any revision or explant procedures establish the temporal sequence central to causation. Records from all treating physicians are relevant.

Obtain the device manufacturer and model information. Device identification from surgical records, patient cards, or explant reports is essential for identifying the proper defendants and evaluating the applicable preemption framework.

Research FDA adverse event reports and recalls. The FDA MAUDE (Manufacturer and User Facility Device Experience) database, FDA recall announcements, and FDA safety communications provide documentary evidence of known risks and manufacturer knowledge.

Identify active MDL or JCCP proceedings. For widely-implanted devices with known complication patterns, existing MDL or JCCP proceedings may already address the injury category. Identification of active consolidation enables coordination with specialized counsel.

Consult with specialized medical device litigation counsel early. Medical device litigation is specialized practice requiring familiarity with federal preemption doctrine, FDA regulatory frameworks, MDL and JCCP practice, and the specific medical and engineering landscape of the device at issue. Early consultation preserves evidence and identifies the optimal venue and strategy.

Document the progression of injury and its impact. Photographs, journal entries, functional limitation records, and contemporaneous documentation of symptom development support both causation and damages.

Preserve electronic records. Communications with healthcare providers, patient support materials from the manufacturer, and any direct-to-consumer advertising encountered may be relevant to the warning adequacy analysis.

Understand the litigation timeline. Medical device cases typically require 24–48 months from filing to resolution. MDL and JCCP proceedings often require longer for bellwether trials and aggregate settlement development. For PMA devices, preemption motion practice frequently extends preliminary litigation by 6–12 months before substantive discovery proceeds.

Frequently Asked Questions

What is the difference between a 510(k) device and a PMA device? A 510(k) device is cleared by the FDA based on substantial equivalence to a legally marketed predicate device — a comparative standard that does not involve independent FDA safety and effectiveness determination. A PMA device is approved by the FDA through the Pre-Market Approval process involving extensive clinical data evaluation. Class III devices typically require PMA; most Class II devices use the 510(k) pathway. The distinction is fundamental to preemption analysis because PMA produces device-specific federal requirements that can preempt state law claims, while 510(k) does not.

Can I sue a medical device manufacturer in California? Yes, subject to the federal preemption framework. For 510(k) cleared Class II devices, the full California product liability framework applies — manufacturing defect, design defect, and failure-to-warn claims are all available. For PMA Class III devices, claims are largely preempted under Riegel v. Medtronic except for claims that parallel federal requirements. Parallel claim pleading is technical and requires specialized counsel.

What is the Riegel preemption doctrine? Riegel v. Medtronic (2008) held that the Medical Device Amendments express preemption provision preempts state law tort claims against Class III PMA devices when those claims would impose requirements different from or in addition to federal requirements established through the PMA process. The practical effect is substantial preemption of standard product liability claims against PMA devices, with the parallel claims exception providing a narrow pathway for claims that track federal requirements.

What is a parallel claim in medical device litigation? A parallel claim is a state law tort claim that seeks to impose requirements identical to federal requirements rather than different or additional requirements. To survive both Riegel express preemption and Buckman implied preemption, the plaintiff must allege conduct violating state law that also violates specific federal requirements, without relying on the federal violation itself as the substantive basis of the claim. Parallel claims are technical to plead and typically require specialized counsel familiar with FDA regulatory requirements.

Does the MICRA cap apply to California defective medical device cases? No. MICRA applies only to medical malpractice claims against healthcare providers. Product liability claims against medical device manufacturers are not subject to MICRA caps. Economic and non-economic damages in California medical device litigation are uncapped.

What is the statute of limitations for California defective medical device claims? Two years from the date of injury under CCP § 335.1 for ordinary claims. Delayed discovery extends the deadline when the causal connection between the device and the injury was not reasonably discoverable. Toxic exposure cases are governed by CCP § 340.8 with a two-year discovery-based period. Implant cases with long-latency complications routinely use delayed discovery to preserve filing rights.

Should I join an MDL or file an individual case? The decision depends on the strength of the individual case, the consolidated proceeding's settlement structure, and strategic preferences. MDL participation provides efficiency benefits and leverages shared discovery costs, but individual cases proceeding outside MDL can produce larger individual recoveries in strong cases. Early consultation with specialized counsel allows evaluation of the optimal pathway.

DISCLOSURE 

This page is published and maintained by 1000Attorneys.com, a California State Bar Certified Lawyer Referral and Information Service, LRIS Certificate No. 0128, accredited by the American Bar Association and established in 2005. The information on this page is for general educational purposes only and is not legal advice. 1000Attorneys.com is not a law firm and does not provide legal representation. For legal advice about your specific situation, consult a qualified California attorney licensed to practice in the jurisdiction where your claim arises.